Hematology-Oncology
Park, Young Suk
95 AppointmentProfessor, Department of Hematology and Oncology, Samsung Medical Center
Speciality Interests
Schedule
04 | MON 29 |
TUE 30 |
WEN 01 |
THU 02 |
FRI 03 |
---|---|---|---|---|---|
AM | available | available | |||
PM |
Medical School
1998~1999 Ph.D. in Medicine Graduate School, Korea University College of Medicine, Seoul, Korea 1982~1986 M.D. Seoul National University College of Medicine, Seoul, Korea
Specialty Training
Fellowship | 1990~1991 Hematology and Medical Oncology, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea | |
---|---|---|
Residency | 1987~1990 Seoul National University Hospital, Seoul, Korea | |
Internship | Seoul National University Hospital |
Other Education
2004~2010 Chief Clinical Trial Training Center Clinical Trial Center, Samsung Medical Center, Seoul, Korea
2000~2003 Chief Center for Clinical Trials, National Cancer Center Hospital, Kyonggi, Korea
1999~2000 Associate Professor Department of Internal Medicine, Halllym University College of Medicine
1996~1997 Consultant University of Pittsburgh National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
1993 Clinical Fellow Fred Hutchinson Cancer Research Center, Seattle, USA
Participation in Academic Societies
and Research
Member Korean Society of Medical Oncology
Member Korean Cancer Association
Member American Society of Clinical Oncology
Thesis
INVEST NEW DRUG 2021 10.1007/s10637-021-01110-9
A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer
ONCOLOGY-BASEL 2021 10.1159/000514404
Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer
ANN ONCOL 2021 10.1016/j.annonc.2020.11.017
A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial
ONCOLOGIST 2021 10.1002/onco.13735
Proton Pump Inhibitor Use and the Efficacy of Chemotherapy in Metastatic Colorectal Cancer: A Post Hoc Analysis of a Randomized Phase III Trial (AXEPT)
THER ADV MED ONCOL 2021 10.1177/1758835921992992
Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors